CoreCap Advisors’s Bicara Therapeutics BCAX Stock Holding History

CoreCap Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$596	Hold	32	–	–	﹤0.01%	2768
2026 Q2	$950	Hold	32	–	–	﹤0.01%	2709
2026 Q1	$636	Hold	32	–	–	﹤0.01%	2613
2025 Q4	$539	Hold	32	–	–	﹤0.01%	2694
2025 Q3	$505	Buy	+32	New	+$358	﹤0.01%	2567

Other funds holding BCAX

RTM

Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Private Trust Company Cleveland, Ohio $1.27B AUM 20.99% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

TWD

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

CoreCap Advisors's BCAX Position: Q3 2026 in Review

CoreCap Advisors held its Bicara Therapeutics (BCAX) position steady in Q3 2026 at 32 shares worth $596. The position accounts for ﹤0.01% of the portfolio, ranked #2768.

CoreCap Advisors first reported a position in BCAX in Q3 2025 and has held it in 5 quarters since. The position peaked at $950 in Q2 2026. 10 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

CoreCap Advisors held 32 shares of Bicara Therapeutics worth $596 as of Q3 2026.
CoreCap Advisors left its Bicara Therapeutics share count unchanged in Q3 2026.
Bicara Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2768 holding.
CoreCap Advisors first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 5 quarters since.
CoreCap Advisors's Bicara Therapeutics position peaked at $950 in Q2 2026.
10 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.